Overview
- In a Nature study, scientists report that Cas12a2 activates when it detects a chosen RNA sequence and then shreds the cell’s DNA to trigger cell death.
- In lab dishes, the system spared healthy cells yet killed those with human papillomavirus (HPV) RNA or a single KRAS cancer mutation, including drug‑resistant cells.
- Researchers also used the method to purge unedited cells after a genome edit, which enriched the remaining pool for correctly edited cells.
- Checks for off‑target effects in these experiments found rare and weak activity, suggesting high specificity that still needs testing in animals.
- Akribion Therapeutics, a 2024 spin‑off from BRAIN Biotech, is advancing the approach toward preclinical development and delivery strategies.